CSF Transport Pathway for Inner Ear Agent Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for hearing loss, including hearing aids and cochlear implants, are insufficient in restoring full auditory function, and gene therapy beyond post-natal stages has proven unsuccessful with invasive procedures that can damage inner ear structures.

Innovation Solution

A method for delivering therapeutic agents to the inner ear by administering them to the cerebrospinal fluid (CSF), using agents such as nucleic acids, vectors, or cells, which can include genes like VGLUT3 or stem cells, to target and restore hearing loss.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If gene therapy is administered through intracochlear or intravestibular injections in early post-natal mice, then hearing is restored in models of genetic deafness, but the procedure is invasive and can cause damage to inner ear structures

Engineering Contradiction:

Improvehearing restorationVSAvoiddamage to inner ear structures

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses cerebrospinal fluid (CSF) as an intermediary medium to deliver therapeutic agents to the inner ear. Instead of direct intracochlear injection, the CSF serves as a carrier that transports agents through the cochlear aqueduct to the cochlear space, thereby restoring hearing while avoiding direct mechanical damage to inner ear structures through a non-invasive intracisternal route

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If gene therapy is administered beyond post-natal stages, then therapeutic effect is achieved, but the procedure becomes more difficult and less effective

Engineering Contradiction:

Improvetherapeutic effectVSAvoidadministration difficulty

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent changes the delivery parameter from direct intracochlear injection to intracisternal CSF administration. This parameter change enables effective gene therapy delivery in adult and elderly subjects (beyond post-natal stages) by utilizing the natural CSF flow pathway through the cochlear aqueduct, making the procedure easier and more effective in older populations who would otherwise be difficult to treat

Inventive Principle:

Principle #35Parameter changes

3Reliability

If current therapies using hearing aids or cochlear implants are used, then hearing loss is managed, but full auditory function is not restored

Engineering Contradiction:

Improvehearing loss managementVSAvoidauditory function capacity

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent replaces mechanical hearing aids and cochlear implants with a biological/gene therapy approach. By delivering therapeutic agents (including genes, nucleic acids, or cells) through CSF to regenerate or restore inner ear structures, the system aims to restore full auditory function rather than merely amplifying sound or providing electrical stimulation, thereby increasing auditory function capacity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method effectively delivers therapeutic agents to the inner ear, potentially restoring hearing thresholds and re-establishing auditory synapses, as demonstrated in mouse models of human deafness, with minimal risk of damaging inner ear structures.

Implementation Method 1

CSF transport pathway for delivery of agents to inner ear

Methodology Applied

Scientific EffectCerebrospinal fluid transport: Convection

Data Source

PatentUS20250049957A1CSF transport pathway for delivery of agents to inner ear

Publication Date: 2025.02.13 UNIVERSITY OF COPENHAGEN

AI summary

This disclosure relates to delivery of various agents to the inner ear of a subject.